Brief: Nxera Pharma Says Workforce Reduction Of About 15% Across Japan & UK Operations

Nxera Pharma

17/11/2025 07:34

Nov 17 (Reuters) - Nxera Pharma Co Ltd 4565.T:

NXERA PHARMA CO LTD: ANNOUNCES FOCUSED RESTRUCTURING TO ENHANCE PATH TO PROFITABILITY

NXERA PHARMA CO LTD - EXECUTIVE TEAM REDUCED FROM TEN 10 TO SEVEN 7 BY MARCH 2026

NXERA PHARMA CO LTD - ONE-TIME RESTRUCTURING CHARGES OF APPROXIMATELY JPY500M WILL BE RECOGNIZED IN FY2025

NXERA PHARMA CO LTD - WILL REDUCE FY2026 CASH RESEARCH AND DEVELOPMENT EXPENDITURE BY ABOUT JPY3.5BN AT PHARMACEUTICAL OPERATIONS IN CAMBRIDGE, UK

NXERA PHARMA: INTENDS TO IMPLEMENT INITIATIVES TO REDUCE OPERATING EXPENSES TO SUPPORT NXERA’S 2030 VISION OF ≥JPY50 BILLION IN NET SALES

NXERA PHARMA - WORKFORCE REDUCTION OF ABOUT 15% ACROSS JAPAN & UK OPERATIONS

NXERA PHARMA  - ONE-TIME RESTRUCTURING CHARGES OF ABOUT JPY500M WILL BE RECOGNIZED IN FY2025

NXERA PHARMA  - STRATEGIC FOCUS WILL BE ON THE DEVELOPMENT OF NEXT-GENERATION THERAPIES FOR OBESITY, METABOLIC AND ENDOCRINE DISORDERS

NXERA PHARMA-  IDENTIFIED PROGRAMS THAT ARE NO LONGER PRIORITY FOR COMMERCIAL REASONS, AND THESE WILL BE READIED FOR PARTNERSHIP OR TERMINATION

Source text: [ID:]

Further company coverage: 4565.T

 ((Reuters.Briefs@thomsonreuters.com;))